3 High Growth GLP-1 Biotech Winners to Buy in July
From the article
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July
Continue reading on 24/7 Wall St.You might also wanna read
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p
theverge.com·1mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·20d ago
GLP-1 Drug Use Triples In Two Years As American Obesity Rate Falls, Gallup Finds
Foreign Policy Journal·6h ago
Obesity in retreat as GLP-1 use nearly quadruples: New data paints a different picture for manufacturers
BakeryAndSnacks·7h ago
Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials
Fierce Biotech·2d ago
Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development
The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w
statnews.com·6mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.